



TERUMO INTERVENTIONAL SYSTEMS

Press Contact: Robert J. Murphy
The Storch-Murphy Group
(908) 276-0777
rmurphy@storchmurphy.com

FOR IMMEDIATE RELEASE

**TERUMO INTERVENTIONAL SYSTEMS EXPANDS WITH
THE FIRST AZUR® DETACHABLE 35 HYDROCOIL® SYSTEM**

*Terumo's New AZUR Detachable 35, with HydroCoil Technology, Marks the First Detachable .035" Coil
That Can Be Released with the Simple Press of a Button*

SOMERSET, NJ -- (December 17, 2010) – Terumo Interventional Systems, a strategic business unit of Terumo Medical Corporation, and leading manufacturer of guidewires, catheters, sheaths, and embolization products, today announced the nationwide availability of the AZUR Peripheral HydroCoil 35 platinum coil embolization system—the first truly detachable hydrogel polymer embolic device to feature larger 0.035” coils designed to provide greater filling capacity, packing density, and mechanical occlusion particularly in the treatment of high-flow and challenging blood vessels, vascular malformations, and aneurysms.

The hydrogel coating undergoes limited expansion within the first three minutes, and fully expands within 20 minutes offering nearly four times more filling volume than a platinum coil of the same size. The AZUR Detachable 35 deploys rapidly - taking less than a second - while offering physicians the flexibility to position and observe the behavior of the coil in the vasculature prior to detachment. A key advantage is that the AZUR Detachable 35 can be retracted and repositioned until it is securely placed, reducing the risk of non-target embolization and coil migration. In addition, the AZUR Detachable 35 is the only hydrogel embolic indicated for peripheral applications that is detachable and compatible with 0.038” lumen catheters. The microporous expandable hydrogel is biologically inert and provides scaffolding for natural tissue proliferation.

- more -

The addition of the AZUR Detachable 35 complements the existing AZUR product line, which includes Detachable 18 coils, Framing 18 coils (platinum only and in a complex 3D shape), Pushable 18 coils, and Pushable 35 coils.

"In our experience, the AZUR Detachable 35 is an excellent embolization system that is very capable of treating higher capacity lesions with fewer coils, while effectively minimizing risk of coil migration," said Craig Greben, M.D., Chief, Division of Vascular and Interventional Radiology, North Shore University Hospital, Manhasset, NY. "The larger coil size is highly deliverable and provides us with added confidence in treating high-blood flow areas or particularly challenging anatomies."

The new AZUR Detachable 35 is intended to reduce or block the rate of blood flow in vessels of the peripheral vasculature. It is designed for use in the interventional radiologic management of arteriovenous malformations, arteriovenous fistulae, aneurysms, and other lesions of the peripheral vasculature.

"The positive feedback we are receiving from our customers about the AZUR Detachable 35 is remarkable and we are confident that this product line expansion will increase Terumo Interventional System's overall leadership position in endovascular embolization," says Chris Pearson, Director of Marketing, Terumo Interventional Systems. "We are committed to providing solutions that further meet the needs of our customers to create better patient outcomes."

For more information about AZUR 35, customers can contact Terumo Interventional Systems by calling its Inside Sales Specialist Team at 800-862-4143 or by visiting <http://www.terumo.com>.

Terumo Interventional Systems

Terumo Interventional Systems (TIS), a strategic business unit of Terumo Medical Corporation, directly markets a full line of guidewires, catheters, introducer sheaths, guiding sheaths and embolization products for use in a multitude of different interventional procedures.

Interventional Radiologists, Interventional Neuroradiologists, Interventional Cardiologists, and Vascular Surgeons are among the medical professionals that depend upon TIS products to access and cross difficult-to-reach lesions, thereby allowing therapeutic intervention in previously unreachable vascular beds.

Terumo Medical Corporation

Founded in 1972 as a Terumo Corporation subsidiary, Terumo Medical Corporation (TMC) develops, manufactures, and markets high-quality medical devices used in a broad range of applications in numerous healthcare markets. TMC manufactures a broad portfolio of needles and syringes, entry-site management products, and a line of sterile connection devices used in hospitals and blood banks worldwide.

- more -

Terumo Corporation

Tokyo-based Terumo Corporation is one of the world's leading medical device manufacturers with \$3.0 billion in sales and operations in more than 160 nations. Founded in 1921, the company develops, manufactures, and distributes world-class medical devices including products for use in cardiothoracic surgery, interventional procedures, and transfusion medicine; the company also manufactures a broad array of syringe and hypodermic needle products for hospital and physician office use. Terumo contributes to society by providing valued products and services to the healthcare market and by responding to the needs of healthcare providers and the people they serve.

Terumo Corporation's shares are listed on the first section of the Tokyo Stock Exchange (No. 4543, Reuters symbol <4543.T>, or Bloomberg 4543: JP) and is a component of the Nikkei 225, Japan's leading stock index.

###